About the Company
arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ARVN News
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
NEW HAVEN, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company ...
Arvinas gets new chief medical head
Clinical-stage biotech company Arvinas appoints Dr. Noah Berkowitz as CMO, leading the development of their oncology and neuroscience programs.
Arvinas, Inc. (ARVN) Interactive Stock Chart - Yahoo Finance
NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation ...
Arvinas: Behind The Huge Rally
Arvinas, Inc. is headquartered in New Haven, CT. This small-cap concern is focused on the development and eventual commercialization of therapies to degrade disease-causing proteins. The stock ...
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Feb. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial ...
Arvinas Holding Company: Buy Rating Backed by Promising Breast Cancer Therapy and Strategic Expansion into Parkinson’s Disease Treatment
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), with a price target of $90.00. Andrew Fein has given his Buy rating due to a ...
Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?
Shares of Arvinas, Inc. (ARVN) have gained 23.1% over the past four weeks to close the last trading session at $46.51, but there could still be a solid upside left in the stock if short-term price ...
Arvinas Inc.: Arvinas Announces Chief Financial Officer Transition
Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that ...
Arvinas, Inc. (ARVN)
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -90.23% and 210.76%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
ARVN Arvinas Inc Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update – Enrollment continues globally in multiple clinical studies of vepdegestrant ...
Loading the latest forecasts...